CDK4/6 Inhibitors in Breast Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1923
Special Issue Editors
2. Breast Cancer Group, Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
Interests: breast cancer; CDK4/6 inhibitors; PI3K/AKT/mTOR pathway; molecular alterations and evolution; development of new drugs; liquid biopsie
Special Issue Information
Dear Colleagues,
CDK4/6 inhibitors have changed the treatment landscape of hormone receptor-positive (HR+)/HER2-negative breast cancer, with consistent improvements in progression-free and overall survival in the metastatic setting and, more recently, invasive disease-free survival in the early setting. However, some questions regarding their use, differences between agents, efficacy—overall and beyond HR+/HER2-negative disease—and adverse event profiles remain to be elucidated. Moreover, the study of the mechanisms of resistance to CDK4/6 inhibitors is an area of intense research, with the ultimate aim to prevent their appearance and to inform subsequent lines of therapy. In this Special Issue, we want to address these questions and provide a comprehensive view of the current knowledge regarding CDK4/6 inhibitors in breast cancer and the avenues for research ahead.
Dr. Mafalda Oliveira
Dr. Meritxell Bellet
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
